OraSure's Regulatory Detour: IntelliQ Withdrawal Clouds a Strong Growth Quarter

Revenue and margins beat, but flagship CT/NG test is delayed; Colli-Pee and public-health products aim to bridge the gap.

OSUR · Earnings Call · 2026-08-05

The Pivot Takes Shape

OraSure's Q2 2026 results reinforced that the multi-year transformation is beginning to pay off. Revenue of $30.6M came in above guidance, growing 9.7% sequentially, with both Diagnostics and Sample Management Solutions contributing. Gross margin expanded 120bps sequentially to 43.5%, driven by "lower scrap and operational efficiencies" — tangible evidence that the in-sourcing and manufacturing consolidation efforts are landing. As CEO Carrie Eglinton Manner noted, “Q2 demonstrated that transition beginning to take shape through stronger revenue, improving margins and meaningful innovation milestones.” — Carrie Eglinton Manner · 2026-08-05 But the quarter's defining moment was not the beat — it was the surprise withdrawal of the IntelliQ CT/NG submission to the FDA. The company had previously guided to a 2026 clearance and launch, and the market had been pricing that catalyst in. The IntelliQ molecular self-test was a centerpiece of the decentralized STI strategy, and its delay raises questions about the near-term growth narrative.

The Regulatory Roadblock

Carrie explained, “Following constructive conversations with FDA, however, we recently elected to withdraw our submission. We are incorporating feedback from the agency, and we will be working with them on resubmission to bring it to market.” — Carrie Eglinton Manner · 2026-08-05 The company remains confident in the product's performance, but the timing is now uncertain. CFO Ken McGrath emphasized that the financial impact is manageable: “this will not incrementally add to our overall cash flow from operations usage. There is an offset here related to the milestone payments that will be reduced.” — Kenneth J. McGrath · 2026-08-05

"We are clearly disappointed in that delayed timing. Obviously, we were working hard toward a-- to work toward clearance and launch. But in terms of our exit expectations for the year, I want to reiterate, it does not change our outlook on growth for the year." — Carrie Eglinton Manner
Carrie Eglinton Manner · 2026-08-05

The withdrawal also triggered a reduction in the contingent consideration liability, providing a modest accounting offset. But the strategic question remains: can the company's other near-term catalysts fill the void?

Growth Drivers Beyond the Setback

OraSure is leaning on a portfolio of new products to carry momentum into H2. The Colli-Pee urine collection kit received FDA clearance in June, with its NUCLEO-PRECISION chemistry for use with Roche's cobas STI tests. The company described early interest as strong: "The Colli-Pee launch is off to a nice start as customers are expressing strong interest in the innovation." Similarly, the FDA clearance of the OraQuick Ebola 2.0 rapid test — developed with BARDA — reinforces OraSure's public-health credentials and global reach. The international portfolio is diversifying beyond HIV. The Sickle SCAN acquisition is already delivering: "SickleSCAN revenue is growing 2x as fast in 2026 as it did in 2025." Near-shoring of the OraQuick HIV self-test is progressing, positioning the company for more resilient local supply chains as funding structures evolve. Sample Management Solutions also showed signs of recovery, with sequential growth across advanced genetic testing labs and microbiome applications. The UK NICE draft guidance for Ziwig Endotest — which uses DNA Genotek's saliva collection technology — is a strong third-party validation of the company's platform, even if it won't move the needle immediately.

Financial Health and Guidance

Financially, OraSure remains in a strong position: zero debt and $161M in cash. The company paused share repurchases to prioritize launch-related investments, but has already returned $22M to shareholders (~10% of shares outstanding). Operating cash flow was -$9.9M in Q2, consistent with expectations, and management reiterated a path to breakeven by early 2027. Guidance for Q3 revenue of $29.5–32.5M implies a sequential decline, reflecting typical seasonality and the absence of the IntelliQ launch. Gross margin is expected to hold at Q2 levels. The $30.6M revenue in Q2 was a solid step, but the company will need Colli-Pee volume and continued SMS momentum to hit its targets. The market reaction has been muted — the stock is up 31% over the last 90 days, but the IntelliQ delay introduces a new overhang. As Carrie noted, “we plan to resubmit it. This is a recent discussion. And in terms of timing, we plan to come back to share more on that.” — Carrie Eglinton Manner · 2026-08-05 Investors are left to weigh the credibility of the resubmission timeline against the evident progress in the core business. In prior quarters, management flagged the risk of pre-commercialization hype. In May 2026, Carrie said, “When you have the product launch expectation, everybody starts gearing up. There is an important distinction to be made... with FDA, with FDA-cleared products, unlike research use only, you really can't premarket.” — Carrie Eglinton Manner, President and Chief Executive Officer · 2026-05-06 That cautious tone now seems prescient. OraSure's story is one of steady operational execution punctuated by regulatory uncertainty. The fundamentals are improving — revenue is stabilizing, gross margins are rising, and the pipeline is deeper than a year ago. But the market's patience will be tested until IntelliQ returns to the regulatory path. For now, the company's rapid test franchise and SMS recovery provide a credible bridge.